These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27238880)

  • 21. Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib.
    Todo M; Shirotake S; Nishimoto K; Yasumizu Y; Kaneko G; Kondo H; Okabe T; Makabe H; Oyama M
    Anticancer Res; 2019 Feb; 39(2):999-1004. PubMed ID: 30711987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Frequent gout attacks during therapy - what can be done?].
    Füessl HS; Stiefelhagen P
    MMW Fortschr Med; 2013 May; 155(9):25. PubMed ID: 23951646
    [No Abstract]   [Full Text] [Related]  

  • 23. The Impact of Pazopanib on the Cardiovascular System.
    Justice CN; Derbala MH; Baich TM; Kempton AN; Guo AS; Ho TH; Smith SA
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):387-398. PubMed ID: 29706106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pazopanib in renal cell carcinoma.
    Sternberg CN
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
    Miaris N; Maltezou M; Papaxoinis G; Visvikis A; Samantas E
    Clin Genitourin Cancer; 2017 Feb; 15(1):e99-e103. PubMed ID: 27601362
    [No Abstract]   [Full Text] [Related]  

  • 27. Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.
    van Kalleveen MW; Walraven M; Hendriks MP
    Invest New Drugs; 2018 Jun; 36(3):513-516. PubMed ID: 29464464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis.
    Elhalawani H; Heiba M; Abdel-Rahman O
    Clin Genitourin Cancer; 2017 Jun; 15(3):e325-e335. PubMed ID: 28189432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
    N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab.
    Zhong YY; McLean L; Buckle A; Siva S; Tran B
    Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term response to pazopanib in an elderly man with mRCC. A case report.
    D'Aniello C; Cavaliere C; Pisconti S; Facchini G
    Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
    Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.
    Kempton A; Justice C; Guo A; Cefalu M; Makara M; Janssen P; Ho TH; Smith SA
    Clin Exp Hypertens; 2018; 40(6):524-533. PubMed ID: 29172746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
    Hioki T; Takama H; Makita S; Chen KR; Watanabe D; Akiyama M
    Eur J Dermatol; 2017 Oct; 27(5):546-547. PubMed ID: 29084643
    [No Abstract]   [Full Text] [Related]  

  • 39. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
    Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
    Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.